Loading...
Market
In how many countries will the new small molecule pill for sickle cell disease be available by the end of 2025?
2
Resolution / Starting Odds
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Company press releases and market reports
Story
New Small Molecule Pill Offers Safer Treatment for Sickle Cell Disease, Published in Science Magazine
Jul 4, 2024, 06:20 PM
A groundbreaking discovery in the treatment of sickle cell disease has been published in Science Magazine. Researchers have developed a small molecule pill that acts as an epigenetic modifier to inhibit fetal hemoglobin, offering a less dangerous and potentially more accessible alternative to CRISPR genome editing, such as Casgevy. This new approach could open up treatment options globally, reducing the need for toxic conditioning. The study, led by a team including Pamela Ting and Jay Bradner, marks a significant advancement in chemical biology and the development of molecular glue degraders.
View original story
Similar markets
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 50 • 25%
50 to 80 • 25%
81 to 120 • 25%
More than 120 • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%
Less than 5 countries • 25%
5 to 10 countries • 25%
11 to 20 countries • 25%
More than 20 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%